Traders work on the floor of the New York Stock Exchange
Following are the US stocks that were actively trading in the Monday morning session. The stocks include Global Crossing, American Medical Systems, Level 3 and Community Health Systems. REUTERS

Shares of companies active in Friday's early trade are Nike Inc., Cisco Systems, Lorillard Inc., LDK Solar Co., Celera, Under Armour and Longtop Financial Technologies.

Losers:

Shares of Nike (NYSE: NKE) plunged 9 percent to $78.90 in early trading after the company reported lower-than-expected third quarter profit on weaker margins and higher costs. The company posted quarterly net income of $523 million or $1.08 per share compared to $497 million or $1.01 per share in the same quarter last year, while analysts estimated net income of $1.11 per share.

Under Armour, Inc. (NYSE: UA) declined 5.8 percent to $63.19 in early trade after weak results from sector rival Nike.

LDK Solar Co. (NYSE: LDK) fell 8.5 percent to $11.45. The Chinese solar PV maker posted earnings per ADR of $1.09 for the fourth quarter on revenue of $921 million, higher than estimates for earnings per ADR of $0.90 and revenue of $871 million. The company’s first quarter forecast was generally in-line with estimates.

Gainers:

Cisco Systems, Inc. (NASDAQ:CSCO) rose 2 percent to $17.33 after the company said it intends to pay a cash dividend to shareholders for the first time.

Lorillard, Inc. (NYSE: LO) gained 8 percent to $85.10 in early trade. According to a report from Wall Street Journal, a U.S. Food and Drug Administration panel said removal of menthol cigarettes from the U.S. market would benefit the public health.

ADR's of Longtop Financial Technologies Limited (NYSE: LFT) surged 12 percent to $33.50 in early trade on Friday. In the past 52 weeks, the stock has traded in the range of $32.48 to $34.79.

Shares of Celera Corp. (NASDAQ:CRA) climbed 31.18 percent after Quest Diagnostics Inc. (NYSE: DGX) announced an agreement to acquire the diagnostics kit maker for $8 per share to gain immediate access to genetic tests and pipeline of biomarkers.